Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles

Ju Yen Fu, David R. Blatchford, L. Tetley, Christine Dufès

Research output: Contribution to journalArticle

  • 24 Citations

Abstract

The therapeutic potential of tocotrienol, an extract of vitamin E with anti-cancer properties, is hampered by its failure to specifically reach tumors after intravenous administration, without secondary effects on normal tissues. We hypothesize that the encapsulation of tocotrienol-rich fraction (TRF) within vesicles bearing transferrin, whose receptors are overexpressed on many cancer cells, could result in a selective delivery to tumors after intravenous administration. The objectives of this study are therefore to prepare and characterize transferrin-targeted vesicles encapsulating TRF, and to evaluate their therapeutic efficacy in vitro and in vivo. The entrapment of TRF in transferrin-bearing vesicles led to a 3-fold higher TRF uptake and more than 100-fold improved cytotoxicity in A431 (epidermoid carcinoma), T98G (glioblastoma) and A2780 (ovarian carcinoma) cell lines compared to TRF solution. The intravenous administration of TRF encapsulated in transferrin-bearing vesicles led to tumor regression and improvement of animal survival in a murine xenograft model, contrary to that observed with controls. The treatment was well tolerated by the animals. This work corresponds to the first preparation of a tumor-targeted delivery system able to encapsulate tocotrienol. Our findings show that TRF encapsulated in transferrin-bearing vesicles is a highly promising therapeutic system, leading to tumor regression after intravenous administration without visible toxicity.
LanguageEnglish
Pages95-99
Number of pages5
JournalJournal of Controlled Release
Volume140
Issue number2
DOIs
StatePublished - 3 Dec 2009

Fingerprint

Tocotrienols
Transferrin
Intravenous Administration
Neoplasms
Transferrin Receptors
Therapeutics
Glioblastoma
Vitamin E
Heterografts
Squamous Cell Carcinoma
Carcinoma

Keywords

  • tocotrienol
  • cancer therapy
  • transferrin
  • tumor targeting
  • delivery system

Cite this

@article{9cbda31f8ef4489382c5ff78fa091ee1,
title = "Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles",
abstract = "The therapeutic potential of tocotrienol, an extract of vitamin E with anti-cancer properties, is hampered by its failure to specifically reach tumors after intravenous administration, without secondary effects on normal tissues. We hypothesize that the encapsulation of tocotrienol-rich fraction (TRF) within vesicles bearing transferrin, whose receptors are overexpressed on many cancer cells, could result in a selective delivery to tumors after intravenous administration. The objectives of this study are therefore to prepare and characterize transferrin-targeted vesicles encapsulating TRF, and to evaluate their therapeutic efficacy in vitro and in vivo. The entrapment of TRF in transferrin-bearing vesicles led to a 3-fold higher TRF uptake and more than 100-fold improved cytotoxicity in A431 (epidermoid carcinoma), T98G (glioblastoma) and A2780 (ovarian carcinoma) cell lines compared to TRF solution. The intravenous administration of TRF encapsulated in transferrin-bearing vesicles led to tumor regression and improvement of animal survival in a murine xenograft model, contrary to that observed with controls. The treatment was well tolerated by the animals. This work corresponds to the first preparation of a tumor-targeted delivery system able to encapsulate tocotrienol. Our findings show that TRF encapsulated in transferrin-bearing vesicles is a highly promising therapeutic system, leading to tumor regression after intravenous administration without visible toxicity.",
keywords = "tocotrienol, cancer therapy, transferrin, tumor targeting, delivery system",
author = "Fu, {Ju Yen} and Blatchford, {David R.} and L. Tetley and Christine Duf{\`e}s",
year = "2009",
month = "12",
day = "3",
doi = "10.1016/j.jconrel.2009.08.017",
language = "English",
volume = "140",
pages = "95--99",
journal = "Journal of Controlled Release",
issn = "0168-3659",
number = "2",

}

Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles. / Fu, Ju Yen; Blatchford, David R.; Tetley, L.; Dufès, Christine.

In: Journal of Controlled Release, Vol. 140, No. 2, 03.12.2009, p. 95-99.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles

AU - Fu,Ju Yen

AU - Blatchford,David R.

AU - Tetley,L.

AU - Dufès,Christine

PY - 2009/12/3

Y1 - 2009/12/3

N2 - The therapeutic potential of tocotrienol, an extract of vitamin E with anti-cancer properties, is hampered by its failure to specifically reach tumors after intravenous administration, without secondary effects on normal tissues. We hypothesize that the encapsulation of tocotrienol-rich fraction (TRF) within vesicles bearing transferrin, whose receptors are overexpressed on many cancer cells, could result in a selective delivery to tumors after intravenous administration. The objectives of this study are therefore to prepare and characterize transferrin-targeted vesicles encapsulating TRF, and to evaluate their therapeutic efficacy in vitro and in vivo. The entrapment of TRF in transferrin-bearing vesicles led to a 3-fold higher TRF uptake and more than 100-fold improved cytotoxicity in A431 (epidermoid carcinoma), T98G (glioblastoma) and A2780 (ovarian carcinoma) cell lines compared to TRF solution. The intravenous administration of TRF encapsulated in transferrin-bearing vesicles led to tumor regression and improvement of animal survival in a murine xenograft model, contrary to that observed with controls. The treatment was well tolerated by the animals. This work corresponds to the first preparation of a tumor-targeted delivery system able to encapsulate tocotrienol. Our findings show that TRF encapsulated in transferrin-bearing vesicles is a highly promising therapeutic system, leading to tumor regression after intravenous administration without visible toxicity.

AB - The therapeutic potential of tocotrienol, an extract of vitamin E with anti-cancer properties, is hampered by its failure to specifically reach tumors after intravenous administration, without secondary effects on normal tissues. We hypothesize that the encapsulation of tocotrienol-rich fraction (TRF) within vesicles bearing transferrin, whose receptors are overexpressed on many cancer cells, could result in a selective delivery to tumors after intravenous administration. The objectives of this study are therefore to prepare and characterize transferrin-targeted vesicles encapsulating TRF, and to evaluate their therapeutic efficacy in vitro and in vivo. The entrapment of TRF in transferrin-bearing vesicles led to a 3-fold higher TRF uptake and more than 100-fold improved cytotoxicity in A431 (epidermoid carcinoma), T98G (glioblastoma) and A2780 (ovarian carcinoma) cell lines compared to TRF solution. The intravenous administration of TRF encapsulated in transferrin-bearing vesicles led to tumor regression and improvement of animal survival in a murine xenograft model, contrary to that observed with controls. The treatment was well tolerated by the animals. This work corresponds to the first preparation of a tumor-targeted delivery system able to encapsulate tocotrienol. Our findings show that TRF encapsulated in transferrin-bearing vesicles is a highly promising therapeutic system, leading to tumor regression after intravenous administration without visible toxicity.

KW - tocotrienol

KW - cancer therapy

KW - transferrin

KW - tumor targeting

KW - delivery system

U2 - 10.1016/j.jconrel.2009.08.017

DO - 10.1016/j.jconrel.2009.08.017

M3 - Article

VL - 140

SP - 95

EP - 99

JO - Journal of Controlled Release

T2 - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -